Ignacio Asial
Founder/CEO
DotBio
10/10Traction
The startup develops antibody therapies that target the interactions between tumors and the tumor microenvironment to enhance immune response. Their approach enables the identification of molecules that reactivate the tumor immune response, addressing the urgent need for effective oncology treatments.
- Biotechnology
Updated 20 months ago
Funding
Raised to date
$31.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Gaorong CapitalNo round attributed
- Source unavailable
Funding rounds are not available yet.
Founders
Pär Nordlund
Founder
Product
Problem
Immunotherapies are not effective for most advanced cancers because tumor cells can overexpress and release signaling molecules that reshape the behavior of immune cells in the tumor microenvironment. Traditional methods of creating multi-functional antibodies are challenging and require extensive protein engineering, leading to long development cycles.
Solution
DotBio leverages its DotBody technology platform, based on a modular design concept, to generate multi-functional antibody therapies. The platform uses prefabricated antibody modules with specific functions that can be combined on demand to build bi- and tri-specific antibodies, antibody-drug conjugates (ADCs), and intracellular antibodies. This high-throughput process allows for the rapid generation and testing of numerous prototype molecules with different specificities and configurations in parallel to identify optimal therapeutic candidates. The DotBody technology is combined with Hot-CoFi stabilization technology to improve the stability and solubility of DotBodies, leading to better developability and safety profiles.
Target Audience
The primary target audience includes pharmaceutical companies seeking co-development projects, out-licensing deals for DotBody modules, or drug candidates in DotBio’s pipeline, as well as medical institutions for clinical development partnerships.
Features
- DotBody technology platform for generating human-derived domain antibodies
- Modular design enabling rapid prototyping of multi-functional antibodies
- Hot-CoFi technology for improving antibody stability and solubility
- Capability to produce bi- and tri-specific antibodies, ADCs, and intracellular antibodies
- Phage display technology for isolating DotBody modules with high affinity and specificity
- DB002: A bi-functional antibody targeting PDL1 and CTLA4, showing efficacy in non-small cell lung cancer tumor xenograft animal models
- DB003 and DB005: Target PDL1 and innovative cytokines linked to resistance, showing efficacy in triple-negative breast cancer and non-small cell lung cancer tumor xenograft models